Last reviewed · How we verify
Ornithine aspartate granule
Ornithine aspartate reduces ammonia levels by promoting its incorporation into urea and glutamine synthesis, thereby improving hepatic encephalopathy symptoms.
Ornithine aspartate reduces ammonia levels by promoting its incorporation into urea and glutamine synthesis, thereby improving hepatic encephalopathy symptoms. Used for Hepatic encephalopathy, Hyperammonemia associated with liver disease.
At a glance
| Generic name | Ornithine aspartate granule |
|---|---|
| Sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
| Drug class | Ammonia-lowering agent |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Ornithine aspartate is a combination of the amino acids ornithine and aspartate that enhances ammonia detoxification through two pathways: ornithine facilitates ammonia removal via the urea cycle, while aspartate supports glutamine synthesis. This dual mechanism reduces circulating ammonia concentrations, which are elevated in liver disease and contribute to neurological dysfunction in hepatic encephalopathy.
Approved indications
- Hepatic encephalopathy
- Elevated blood ammonia levels in liver disease
Common side effects
- Gastrointestinal disturbances
- Nausea
- Diarrhea
Key clinical trials
- The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules (PHASE4)
- Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: